Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib  

作　　者：Jianwei Zhang Haibin Zhu Lin Shen Jie Li Xiaoyan Zhang Chunmei Bai Zhiwei Zhou Xianrui Yu Zhiping Li Enxiao Li Xianglin Yuan Wenhui Lou Yihebali Chi Nong Xu Yongmei Yin Yuxian Bai Tao Zhang Dianrong Xiu Jia Chen Shukui Qin Xiuwen Wang Yujie Yang Haoyun Shi Xian Luo Songhua Fan Weiguo Su Ming Lu Jianming Xu 

机构地区：[1]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China [2]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital&Institute,Beijing 100142,China [3]State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers,Beijing Key Laboratory of Carcinogenesis and Translational Research,Department of Gastrointestinal Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China [4]Department of Medical Oncology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China [5]Department of Gastric Surgery,State Key Laboratory of Oncology in South China,Collaborative Innovation Centre for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510062,China [6]Department of Pancreatic and Hepatobiliary Surgery,Fudan University Shanghai Cancer Center,Shanghai 200032,China [7]Department of Abdominal Oncology,West China Hospital,Sichuan University,Chengdu 332001,China [8]Department of Medical Oncology,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China [9]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [10]Department of General Surgery,Zhongshan Hospital of Fudan University,Shanghai 200032,China [11]Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [12]Department of Medical Oncology,the First Affiliated Hospital of Zhejiang University,Hangzhou 310009,China [13]Department of Medical Oncology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China [14]Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China [1

出　　处：《Chinese Journal of Cancer Research》2023年第5期526-535,共10页中国癌症研究（英文版）

摘　　要：Objective:Currently,pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases(PNELM)receiving surufatinib treatment was unsatisfying.Our objective was to examine the association between radiological characteristics and efficacy/prognosis.Methods:We enrolled patients with liver metastases in the phase III,SANET-p trial(NCT02589821)and obtained contrast-enhanced computed tomography(CECT)images.Qualitative and quantitative parameters including hepatic tumor margins,lesion volumes,enhancement pattern,localization types,and enhancement ratios were evaluated.The progression-free survival(PFS)and hazard ratio(HR)were calculated using Cox’s proportional hazard model.Efficacy was analyzed by logistic-regression models.Results:Among 152 patients who had baseline CECT assessments and were included in this analysis,the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative parameters.In the multivariable analysis of patients receiving surufatinib(N=100),those with higher arterial phase standardized enhancement ratio-peri-lesion(ASER-peri)exhibited longer PFS[HR=0.039;95%confidence interval(95%CI):0.003−0.483;P=0.012].Furthermore,patients with a high enhancement pattern experienced an improvement in the objective response ratio[31.3%vs.14.7%,odds ratio(OR)=3.488;95%CI:1.024−11.875;P=0.046],and well-defined tumor margins were associated with a higher disease control rate(DCR)(89.3%vs.68.2%,OR=4.535;95%CI:1.285−16.011;P=0.019)compared to poorlydefined margins.Conclusions:These pre-treatment radiological features,namely high ASER-peri,high enhancement pattern,and well-defined tumor margins,have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.

关 键 词：Neuroendocrine tumors liver metastases computed tomography surufatinib 

分 类 号：R73[医药卫生—肿瘤]